Infections associated with ruxolitinib: study in the French Pharmacovigilance database

Ann Hematol. 2018 May;97(5):913-914. doi: 10.1007/s00277-018-3242-8. Epub 2018 Jan 16.

Authors

Pinel Sylvine¹, Sternjacob Thomas², Eftekhari Pirayeh²; French Network of Regional Pharmacovigilance Centers

Affiliations

¹ French Regional Pharmacovigilance Center, Fernand-Widal Hospital - APHP, 200, rue du faubourg SaintDenis, 75475, Paris, France. sylvine.pinel@aphp.fr.
² French Regional Pharmacovigilance Center, Fernand-Widal Hospital - APHP, 200, rue du faubourg SaintDenis, 75475, Paris, France.

PMID: 29340760
DOI: 10.1007/s00277-018-3242-8

No abstract available

Publication types

Letter

MeSH terms

Databases, Factual
Disease Susceptibility
France / epidemiology
Humans
Immune System / drug effects
Immunocompromised Host
Infections / epidemiology
Infections / etiology*
Janus Kinase 1 / antagonists & inhibitors
Janus Kinase 2 / antagonists & inhibitors
Molecular Targeted Therapy
Nitriles
Pharmacovigilance
Polycythemia Vera / drug therapy
Primary Myelofibrosis / drug therapy
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / adverse effects*
Pyrazoles / pharmacology
Pyrazoles / therapeutic use
Pyrimidines
Retrospective Studies
Signal Transduction / drug effects

Substances

Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ruxolitinib
JAK1 protein, human
JAK2 protein, human
Janus Kinase 1
Janus Kinase 2